The Specialty Drug Shortage Nobody Is Talking About: Access Denials
The Specialty Drug Shortage Nobody Is Talking About: Access Denials
5 minute read
When you cannot get a medication you need, it does not really matter whether the pharmacist says "we don't have it" or "your insurance won't cover it." The outcome is the same: you go home without your medication.
But the cause matters enormously, because the solution is completely different. There is a well-documented shortage of certain specialty drugs caused by manufacturing constraints, supply chain disruptions, and distribution bottlenecks. And then there is an entirely different problem that gets far less attention: the access denial. This is when the drug is available, the pharmacy has it, your doctor wants you to have it, and you still cannot get it because your insurance company has said no.
Access denials and drug shortages look identical from where you sit. But one is a supply problem and the other is a coverage problem. Understanding the difference is the first step toward knowing how to respond.
What an Access Denial Actually Is
An access denial is any coverage barrier that prevents you from receiving a medication that is commercially available. This includes prior authorization denials, step therapy requirements, formulary exclusions, high cost-sharing that makes a drug effectively unaffordable, and specialty tier placements that push cost-sharing beyond what most people can manage.
Specialty drugs are the most heavily affected category. A 2023 analysis found that specialty drugs account for more than 50 percent of all drug spending in the United States despite representing only about 2 percent of all prescriptions.¹ Insurers respond to this cost concentration by applying aggressive utilization management — which means prior authorization, step therapy, high copays, and formulary restrictions hit this drug category harder than any other.
The result is a denial rate for specialty drugs that bears no resemblance to denial rates for standard medications. A 2022 report by the American Journal of Managed Care found that specialty drug prior authorization denial rates were substantially higher than those for non-specialty drugs, with some therapeutic categories (oncology, immunology, rare disease) seeing denial rates that affected a significant proportion of patients at the point of initiation.²
The Confusion With Drug Shortages
Drug shortages are real and serious. The FDA maintains a public database of current shortages at accessdata.fda.gov, and the list is long. Generic drugs, sterile injectables, and some specialty compounds face periodic or persistent shortages due to manufacturing quality issues, ingredient scarcity, and the economics of generic drug production.
The confusion between shortages and access denials is understandable. Both produce the same experience: you try to fill a prescription and it does not happen. But the paperwork looks different.
If your pharmacy says a drug is on backorder or unavailable from their distributor, that is a shortage problem. The solution involves finding a different pharmacy, a compounding pharmacy (for some drugs), or an alternative formulation.
If your pharmacy says the claim was rejected, that your insurance denied it, or that your prior authorization was not approved, that is an access denial. The solution involves an appeal, a step therapy exception, a formulary exception, or a coverage review.
Some patients navigate the wrong problem for weeks before realizing they are in the wrong channel entirely. Clarifying which situation you are in is not a small thing — it can save you significant time and frustration.
Who Gets Hit Hardest by Access Denials
Access denials for specialty drugs fall disproportionately on people with certain categories of chronic illness.
Autoimmune conditions. People with rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, lupus, and multiple sclerosis frequently need high-cost biologics that carry aggressive prior authorization requirements. The step therapy burden in this space is particularly heavy.
Rare diseases. Drugs approved under the FDA's orphan drug designation often have no clinical alternatives, which theoretically should make step therapy less applicable. In practice, insurers sometimes apply step therapy requirements even when no clinically comparable alternatives exist.
Oncology. Oral cancer drugs have historically been subject to different coverage rules than IV chemotherapy, creating a Part B/Part D split (discussed in another post) that has left some patients facing prohibitive out-of-pocket costs for drugs their physician prescribed.
Mental health. Specialty mental health medications, including long-acting injectable antipsychotics and certain newer-generation drugs, are subject to prior authorization at high rates despite federal mental health parity laws that are supposed to prevent discriminatory coverage restrictions.³
What to Do If You Are Facing an Access Denial
The most important thing is to identify it correctly. Ask your pharmacy whether the rejection is a supply issue or a coverage issue. Ask them to read you the rejection code. If it involves prior authorization, step therapy, or a formulary exclusion, you are in access denial territory.
From there, the path forward involves:
Working with your physician's office to understand what the denial says and what documentation would support an appeal or exception request.
Requesting the prior authorization criteria from your insurer so you know exactly what they are looking for.
Checking the manufacturer's patient assistance program. Most manufacturers of high-cost specialty drugs have programs that provide the drug at no or low cost to patients who are uninsured or underinsured, or who are in an active coverage dispute. These programs do not solve the insurance problem, but they can bridge a gap while your appeal is pending.
Filing an appeal if prior authorization was denied, using the steps described in more detail in related posts on this site.
Contacting a patient advocacy organization specific to your condition. Disease-specific advocacy organizations (the Arthritis Foundation, the Multiple Sclerosis Society, the Crohn's and Colitis Foundation, and others) often have patient navigators who work on exactly these access problems.
What This Means for You
If you cannot get your specialty medication, the first question to ask is: is this a shortage or a denial? The answer changes everything about what you do next.
Ellen can help you identify the type of barrier you are facing and build a plan for getting past it. Start here →
Frequently Asked Questions
How do I know if my drug is on the FDA shortage list?
The FDA maintains a searchable database of current drug shortages at fda.gov/drugs/drug-safety-and-availability/drug-shortages. You can search by drug name. If your drug is not on this list and your pharmacy is telling you it is unavailable, the issue may be a distribution or formulary problem rather than a true shortage.
What is a formulary exception?
A formulary exception is a request to your insurer to cover a drug that is not on your plan's covered drug list (formulary), or to cover it at a lower cost-sharing tier than it is currently placed. Most plans have a formulary exception process, and a physician letter documenting why the non-formulary drug is medically necessary is typically required.
Can I get my specialty drug while my appeal is pending?
Sometimes. If your physician certifies urgent medical need, you may be able to access an emergency supply through your pharmacy while the authorization process is ongoing. Manufacturer patient assistance programs can also provide the drug during the appeal window. Ask your doctor's office and your pharmacist what options exist for your specific situation.
Sources: